An impurity of Felypressin. Felypressin is a Vasopressin 1 agonist, and will thus have effects at all Arginine vasopressin receptor 1As. It physiologically effects on vascular SMC's due to the form in which it is administered. Its receptors are found in various sites around the body. The major points include the CNS, Liver, Anterior Pituitary, Muscle (both vascular and non-vascular smooth muscle), and Platelets (CLAMP).
CAT No: 10-101-189
Felypressin Impurity B is a synthetic peptide derivative that serves as a structurally related analog to the parent vasopressin-like peptide, felypressin. As a defined impurity standard, it is characterized by specific sequence modifications that distinguish it from the main active pharmaceutical ingredient. The availability of such peptide impurities is crucial for analytical, quality control, and research applications, particularly in the context of peptide drug development and manufacturing. Felypressin Impurity B holds significance for laboratories and industry professionals working to ensure the identity, purity, and overall safety profile of peptide-based compounds through comprehensive impurity profiling and method validation.
Analytical method development: Felypressin Impurity B is widely used as a reference standard during the development and validation of analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry. Its well-characterized structure allows researchers to optimize separation parameters, assess method sensitivity, and accurately identify and quantify impurity profiles in peptide drug substances. Incorporating known impurities into method development ensures robust detection capabilities and supports the establishment of reliable quality control protocols, which are essential for both research and manufacturing environments.
Quality control and batch release testing: The presence of defined peptide impurities like Felypressin Impurity B enables manufacturers and quality assurance teams to monitor the consistency and purity of felypressin batches. By spiking analytical samples with this impurity, laboratories can verify the specificity and accuracy of their detection methods, ensuring that even trace levels of structurally similar byproducts are identified. This practice is integral to maintaining stringent product specifications and supports the overall integrity of peptide production workflows.
Peptide impurity profiling: Comprehensive impurity profiling is a key aspect of peptide drug characterization, and Felypressin Impurity B plays a central role in this process. Its use facilitates the identification and quantification of minor components that may arise during peptide synthesis, purification, or storage. Understanding the presence and behavior of such impurities contributes to a deeper knowledge of degradation pathways, process-related byproducts, and the chemical stability of the primary peptide. This information is vital for risk assessment and for informing process optimization strategies.
Peptide synthesis process optimization: Insights gained from the detection and quantification of Felypressin Impurity B can inform improvements in synthetic methodologies and purification techniques. By tracking the formation of this and other impurities under various reaction conditions, chemists can refine reagent selection, reaction parameters, and downstream processing steps to minimize impurity formation. Such optimization not only enhances product yield and purity but also supports compliance with industry best practices for peptide manufacturing.
Research in peptide structure-activity relationships: The availability of structurally defined peptide impurities like Felypressin Impurity B also enables investigations into the impact of sequence variations on biological activity, stability, and physicochemical properties. By comparing the characteristics of the impurity with those of the parent peptide, researchers can gain valuable insights into structure-activity relationships, inform the design of improved analogs, and advance the understanding of peptide-based drug candidates. These studies contribute to the broader field of peptide chemistry and support the rational development of next-generation bioactive peptides.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More